Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  ShangPharma Corp (ADR)    SHP

No quotes available
-- USD   0.00%
2014 AbbVie board ditches planned $55 billion Shire acquisition
2013 SHANGPHARMA COR : Rosen Law Firm Announces Investigation of ShangPha..
2012 SHANGPHARMA COR : ShangPharma Announces Third Quarter 2012 Results
SummaryQuotesNewsCalendarCompanyFinancials 
News SummaryMost relevantAll newsSector news 

ShangPharma Corp (ADR) : ShangPharma to Attend Two Upcoming Investor Conferences

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/28/2011 | 11:05am CEST

SHANGHAI, Nov. 28, 2011 /PRNewswire-Asia/ -- ShangPharma Corporation (NYSE: SHP) ("ShangPharma" or the "Company"), a leading China-based pharmaceutical and biotechnology research and development outsourcing company, today announced that it is scheduled to present at the following investor conferences in December 2011:

Ms. Lan Xie, Vice President of Finance and Investor Relations of ShangPharma, will present at the following conferences:

    --  Deutsche Bank 5th Annual MedTools Investor Summit, December 5-6, 2011,
        Boston
    --  Oppenheimer 22nd Annual Healthcare Conference, December 13-14, 2011, New
        York City

Presentation materials will be available under the Webcasts & Presentations section of the Company's investor relations website at http://ir.shangpharma.com.

ABOUT SHANGPHARMA CORPORATION

ShangPharma Corporation (NYSE: SHP) is a leading China-based contract research organization providing high quality and cost-effective services for the pharmaceutical and biotechnology industry. It offers a broad range of high-quality, integrated services across the drug discovery and development process to help international and Chinese pharmaceutical and biotechnology companies discover and develop novel drug candidates efficiently. ShangPharma's services consist of discovery chemistry, discovery biology and preclinical development, pharmaceutical development and biologics services. For more information, please visit www.shangpharma.com.



    For further information, please contact:
    ShangPharma
    Ms. Lan Xie
    VP of Finance and Investor Relations
    Email: ir@shangpharma.com

    Brunswick Group
    Lilian Wong
    Email: shangpharma@brunswickgroup.com
    Phone: 86-10-5960-8600

SOURCE ShangPharma Corporation

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SHANGPHARMA CORP (ADR)
2014 AbbVie board ditches planned $55 billion Shire acquisition
2013 SHANGPHARMA CORP (ADR) : Rosen Law Firm Announces Investigation of ShangPharma C..
2012 SHANGPHARMA CORP (ADR) : ShangPharma Announces Third Quarter 2012 Results
2012 SHANGPHARMA CORP (ADR) : ShangPharma to Report Third Quarter 2012 Financial Resu..
2012 SHANGPHARMA CORP (ADR) : ShangPharma and Harbour Antibodies Announce Licensing A..
2012 SHANGPHARMA CORP (ADR) : ShangPharma Announces Second Quarter 2012 Results
2012 SHANGPHARMA CORP (ADR) : ShangPharma to Report Second Quarter 2012 Financial Res..
2012 SHANGPHARMA CORP (ADR) : ShangPharma Independent Committee Appoints Financial Ad..
2012 SHANGPHARMA CORP (ADR) : ShangPharma Independent Committee Appoints Chairman and..
2012DJU.S. HOT STOCK FUTURES : Hot stocks to watch
More news
Sector news : Biotechnology & Medical Research - NEC
09/29DJARROWHEAD PHARMACEUTICALS : Amgen, Arrowhead Pharma Agree to Cardiovascular Coll..
09/27DJAMGEN : Myeloma Treatment Study Fails to Meet Primary Endpoint
09/26DJSANOFI : FDA Accepts Sanofi's, Regeneron's Dermatitis Treatment for Priority Rev..
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- 2nd Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- Update
More sector news : Biotechnology & Medical Research - NEC